Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.2876 USD
−15.55 M USD
0.00 USD
6.63 M
About Cingulate Inc.
Sector
Industry
CEO
Jennifer L. Callahan
Website
Headquarters
Kansas City
Founded
2012
ISIN
US17248W1137
FIGI
BBG013YMVH68
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.
Displays a symbol's price movements over previous years to identify recurring trends.